Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

Oncotarget’s Top 10 Papers Published in 2023 (Crossref Data)

Oncotarget

February 15, 2024
Read Oncotarget’s Top 10 papers published in 2023 (based on data from Crossref). continue reading »

Genetic and Therapeutic Landscapes in Cohort of Pancreatic Adenocarcinomas Using NGS and Machine Learning

News

February 14, 2024
PRESS RELEASE: On February 5, 2024, a new research paper was published in Oncotarget, entitled, “Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis.” continue reading »

Differential Expression of Mad2 Gene in Human Esophageal Cancer

News

February 12, 2024
PRESS RELEASE: On February 5, 2024, a new research paper was published in Oncotarget, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples.” continue reading »

Genetic Alterations in Thyroid Cancer: Resistance to BRAFi and Anaplastic Transformation

Oncotarget

February 8, 2024
In a new research perspective, researchers discuss the role of genetic alterations in mediating resistance to BRAF inhibition and anaplastic transformation in thyroid cancer. continue reading »

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma

News

February 7, 2024
PRESS RELEASE: On February 5, 2024, a new research perspective was published in Oncotarget, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.” continue reading »